DMT Business Summary

Dynamic Medical Technologies Inc. (DMT), a prominent member of the Excelsior Medical Group, operates as a leading distributor and service provider in the aesthetic medicine sector across Taiwan, Hong Kong, and Mainland China. The company generates revenue through a multi-pronged model encompassing the sale and leasing of high-end aesthetic laser systems, light-based equipment, and body contouring devices, alongside recurring income from medical consumables, dermal fillers (such as the Neuramis line), and specialized cosmeceuticals. DMT further diversifies its income through high-margin maintenance contracts, aesthetician training programs, and clinical operation consulting services. Within the Taiwanese market, DMT maintains a dominant position with an estimated market share exceeding 60% in key laser categories, competing directly with regional players such as SciVision Biotech (1786.TW), Bioptik Technology (4161.TWO), and Pacific Hospital Supply (4126.TWO), while distinguishing itself through a service-to-sales ratio significantly higher than the industry average. The leadership team is anchored by Chairman Fu Hui-dong, a veteran of the Excelsior Medical Group with extensive experience in healthcare infrastructure and strategic investment. The executive operations are led by General Manager (CEO) Chen Po-yuan, who brings a deep technical background in electronic engineering and medical device maintenance, having previously served as a senior executive at 8Emed. Supporting the core leadership are Vice President and CFO Chiang Chih-hao, a former Deloitte auditor with expertise in cross-border financial management, and Accounting Manager Chen Kuan-liang. The company is backed by significant institutional investment from its parent group, Excelsior Medical Co., Ltd., and maintains a board of directors that includes representatives from major healthcare investment vehicles such as Microbio Co., Ltd. and Shin Shin Investment, ensuring a robust governance framework focused on long-term expansion into the anti-aging and biotechnology sectors.